Biomarker docetaxel-based chemotherapy;Biomarker-Docetaxel-basierte Chemotherapie

Urologe - Ausgabe A

Volumn 52, Issue 9, 2013, Pages 1261-1264

  Pfister, D ^a   Heidenreich, A ^a   Porres, D ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Androgen deprivation; Prostate cancer; Prostate specific antigen; Tumor stage; Tumor stage, castration resistant

Indexed keywords

DOCETAXEL; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; HUMAN; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; MALE; NEOPLASM PROTEINS; PREVALENCE; PROGNOSIS; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884703386     PISSN: 03402592     EISSN: 14330563     Source Type: Journal    
DOI: 10.1007/s00120-013-3318-y     Document Type: Article

References (30)

1. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe 2004. Ann Oncol 16(3):481-488
2. Tannock I, deWit R, Berry W et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
3. Petrylak D, Tangen C, Hussain M et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
4. Bono JS de, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147-1154
5. Bono JS de, Logothetis CJ, Molina et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995-2005
6. Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187-1197
7. Parker C, Heinreich D, O'Sullivan JM et al (2011) Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castrationresistant prostate cancer: a phase III randomized trial (ALSYMPCA). Eur J Cancer 47(Suppl 2):3
8. Smaletz O, Scher HI, Small EJ et al (2002) Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20:3972-3982
9. Halabi S, Small EJ, Kantoff PW et al (2003) Prognostic model predicting survival in men with hormone-refractory metastatic prostate cancer J Clin Oncol 21:1232-1237
10. Olbert P, Hegele A, Kraeuter P et al (2006) Clinical significance of a prostate - specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Anticancer Drugs 17(8):993-996
11. Nelius T, Filleur S (2009) PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy. Prostate 69:1802-1807
12. Scher H, Halabi S, Tannock I et al (2008) Design and end pints of clinical trials for patients with progressive prostate cancer and castrate levels of testosteron: recommendations of the Prostate Clinical Trials Working Group. J Clin Oncol 26:1148-1159
13. Armstrong A, Garrett-Mayer E, Yang Y et al (2007) Prostate-specific antigen and pain surrogacy analysis in metastatic hormone refractory prostate cancer. J Clin Oncol 26:3965-3970
14. QU YY, Dai B, Kong YY et al (2013) Prognostic factors in Chinese patients with metastatic castration - resistant prostate cancer treated with docetaxel-based chemotherapy. Asian J Androl 15:110-115
15. Sonpavde G, Pond G, Berry W et al (2012) Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol 30(5):607-613
16. Armstrong A, Garrett-Mayer E, deWit R et al (2010) Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 16:203-211
17. Pond G, Armstrong A, Wood B et al (2012) Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prtostate cancer receiving docetaxel-based chemotherapy. BJU Int 110:461-468
18. Beer T, Lalani A, Lee S et al (2008) C-reactive protein as a prognostic marker form en with androgen-independent prostate cancer: results from the ASCENt trial. Cancer 112:2377-2383
19. Prins R, Rademacher B, Mongoue-Tchokote S et al (2010) C-reactive protein as an adverse prognostic marker form en with castration - resistant prostate cancer (CRPC): confimratory results. Urol Oncol 30:33-37
20. Bono J de, Scher H, Montgomery R et al (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14(19):6302-6309
21. Yoshino T, Shiina H, Urakami S et al (2006) Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res 12:6116-6124
22. Bree C, Savonije J, Franken N et al (2000) The effect of p53-function on the sensitivity to paclitaxel with or without hyperthermia in human colorectal carcinoma cells. Int J Oncol 16(4):739-744
23. Swanson T, Krueger S, Galoforo S et al (2011) TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer. Prostate doi:10.1002/pros.21371
24. Dumontet C, Sikic B (1999) Mechanism of action and of resistance to antitubulin agents: microtubule dynamics, drug transport and cell death. J Clin Oncol 17:1061-1070
25. Ferrandina G, Zannoni G, Martinelli E et al (2006) Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 12:2774-2779
26. Galmarini C, Treilleux I, Cardoso F et al (2008) Class III β - tubulin isotope predictsresponse in advancedbreast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res 14:4511-4516
27. Seve P, Mackey J, Isaac S et al (2005) Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4:2001-2007
28. Terry S, Ploussard G, Allory Y et al (2009) Increased expression of class III β-tubulin in castration resistant human prostate cancer. Br J Cancer 101:951-956
29. Ploussard G, Terry S, Maille P et al (2010) Class III β-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res 70:9253-9264
30. Efstathiou E, Titus M, Tsavachidou D et al (2012) Effects of Abiraterone Acetat on Androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 30:637-643